By acquiring Fusion Pharmaceuticals, AstraZeneca will add multiple radioconjugates to its portfolio, including Fusion’s most advanced radioconjugate, FPI-2265. “Between 30% and 50% of patients with cancer today receive radiotherapy at some point during treatment, and the acquisition of ...
Share this article HAMILTON, ON and BOSTON, June 25, 2020 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (NASDAQ: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the pricing of its initial public off...
FUSION PHARMACEUTICALS INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (In thousands, except share and per share amounts) (Unaudited) Three Months Ended December 31, Year Ended December 31, 2023 2022 2023 2022 Collaboration revenue $ — $ 140 $ 2,068 ...
AMD is expected to announce itsfourth-quarter resultson Tuesday, Feb. 4. Ahead of the event analysts expect the company to report a non-GAAP profit of$0.88 per share, up 49.2% from$0.59 per sharereported in the year-ago quarter. Furthermore,...
June 4, 2024 Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radioconjugates (RCs), announced the successful completion of the acquisition of all of the issued and outstanding shares of Fusion by a wholly-owned subsidiary of Astra...
AstraZeneca is following in the footsteps of some of its big pharmaceutical company peers,plunking down $2 billionto acquire its radiopharmaceuticals partner Fusion Pharmaceuticals. More than adding a pipeline of targeted radiation therapies, AstraZeneca gains the crucial supply chain...
05 June 2024 Acquisition of Fusion completed AstraZeneca today announced the successful completion of the acquisition of Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing next-generation radioconjugates (RCs). The acquisition marks a major step forward in AstraZeneca deliveri...
AstraZeneca has entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing next-generation radioconjugates.
North America Region is Expected to Hold Largest Share in the Spinal Fusion Devices Market Within North America, the United States is expected to have the largest market share. The United States currently dominates the market for spinal surgery devices, and this dominance is expected to continue ...
Insulin Infusion Pump Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029) The report covers Insulin Pump Market Trends, Outlook & Companies and the market is segmented by Component (Pump Device, Infusion Set, and Reservoir), and Geography (North America, Europe, Asia-Pacif...